Mesa Laboratories (MLAB) | Financial Analysis & Statements
Mesa Laboratories Inc. Small-cap Technology
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Dec 2025Income Metrics
Revenue
65.1M
Gross Profit
41.8M
64.18%
Operating Income
8.0M
12.25%
Net Income
3.6M
5.57%
EPS (Diluted)
$0.65
Balance Sheet Metrics
Total Assets
433.3M
Total Liabilities
273.5M
Shareholders Equity
159.8M
Debt to Equity
1.71
Cash Flow Metrics
Operating Cash Flow
14.1M
Free Cash Flow
18.0M
Revenue & Profitability Trend
Quarter Income Flow
Dec 31, 2025
Annual Income Flow
2025
Mesa Laboratories Income Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 241.0M | 216.2M | 219.1M | 184.3M | 133.9M |
| Cost of Goods Sold | 90.1M | 82.9M | 85.4M | 75.2M | 46.9M |
| Gross Profit | 150.9M | 133.2M | 133.7M | 109.1M | 87.0M |
| Gross Margin % | 62.6% | 61.6% | 61.0% | 59.2% | 65.0% |
| Operating Expenses | |||||
| Research & Development | 19.5M | 19.3M | 20.5M | 15.8M | 10.4M |
| Selling, General & Administrative | 115.0M | 111.5M | 109.9M | 88.6M | 64.3M |
| Other Operating Expenses | - | - | - | - | - |
| Total Operating Expenses | 134.5M | 130.8M | 130.4M | 104.4M | 74.7M |
| Operating Income | 16.3M | 2.5M | 3.3M | 4.7M | 12.4M |
| Operating Margin % | 6.8% | 1.1% | 1.5% | 2.6% | 9.2% |
| Non-Operating Items | |||||
| Interest Income | - | - | - | - | 107.0K |
| Interest Expense | 11.9M | 5.7M | 4.8M | 3.9M | 8.0M |
| Other Non-Operating Income | 1.5M | -272.4M | 1.1M | 2.8M | -2.0M |
| Pre-tax Income | 6.0M | -275.6M | -389.0K | 3.6M | 2.3M |
| Income Tax | 7.9M | -21.4M | -1.3M | 1.7M | -971.0K |
| Effective Tax Rate % | 133.1% | 0.0% | 0.0% | 47.6% | -42.2% |
| Net Income | -2.0M | -254.2M | 930.0K | 1.9M | 3.3M |
| Net Margin % | -0.8% | -117.6% | 0.4% | 1.0% | 2.4% |
| Key Metrics | |||||
| EBITDA | 39.5M | 36.2M | 37.5M | 32.5M | 28.0M |
| EPS (Basic) | $-0.36 | $-47.20 | $0.17 | $0.36 | $0.66 |
| EPS (Diluted) | $-0.36 | $-47.20 | $0.17 | $0.35 | $0.64 |
| Basic Shares Outstanding | 5421000 | 5386000 | 5321000 | 5212000 | 4975000 |
| Diluted Shares Outstanding | 5421000 | 5386000 | 5321000 | 5212000 | 4975000 |
Income Statement Trend
Join Our United States Telegram Channel
Get Instant Market Updates: 52-Week High/Low Alerts, Breakout Notifications & Expert Stock Analysis Delivered To Your Phone. Join Traders Making Informed Decisions Daily!
Mesa Laboratories Balance Sheet From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Assets | |||||
| Current Assets | |||||
| Cash & Equivalents | 27.3M | 28.2M | 32.9M | 49.3M | 263.9M |
| Short-term Investments | - | - | - | - | - |
| Accounts Receivable | 42.0M | 39.1M | 42.6M | 41.2M | 23.8M |
| Inventory | 25.4M | 32.7M | 34.6M | 24.6M | 11.2M |
| Other Current Assets | 2.9M | 3.3M | 4.0M | 9.1M | 4.9M |
| Total Current Assets | 102.7M | 109.4M | 119.0M | 124.3M | 303.7M |
| Non-Current Assets | |||||
| Property, Plant & Equipment | 29.9M | 24.9M | 18.9M | 18.9M | 13.2M |
| Goodwill | 460.4M | 473.9M | 789.7M | 832.4M | 433.4M |
| Intangible Assets | 96.9M | 113.8M | 216.8M | 250.1M | 111.7M |
| Long-term Investments | - | - | - | - | - |
| Other Non-Current Assets | 19.7M | 11.8M | 11.4M | 13.1M | 3.1M |
| Total Non-Current Assets | 330.7M | 337.4M | 542.9M | 583.1M | 297.7M |
| Total Assets | 433.3M | 446.8M | 661.8M | 707.4M | 601.5M |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts Payable | 5.7M | 6.0M | 6.1M | 7.9M | 4.5M |
| Short-term Debt | 104.6M | 3.0M | 2.9M | 2.8M | 1.0M |
| Current Portion of Long-term Debt | - | - | - | - | - |
| Other Current Liabilities | - | - | - | - | - |
| Total Current Liabilities | 164.0M | 44.3M | 43.4M | 48.1M | 32.6M |
| Non-Current Liabilities | |||||
| Long-term Debt | 76.9M | 221.7M | 183.3M | 218.4M | 145.7M |
| Deferred Tax Liabilities | 20.2M | 19.8M | 34.0M | 39.2M | 16.3M |
| Other Non-Current Liabilities | 12.5M | 15.6M | 7.7M | 7.9M | 715.0K |
| Total Non-Current Liabilities | 109.6M | 257.1M | 225.0M | 265.5M | 162.7M |
| Total Liabilities | 273.5M | 301.4M | 268.4M | 313.6M | 195.2M |
| Equity | |||||
| Common Stock | 358.5M | 343.6M | 332.1M | 313.5M | 317.7M |
| Retained Earnings | -188.9M | -183.5M | 74.2M | 76.7M | 72.5M |
| Treasury Stock | - | - | - | - | - |
| Other Equity | - | - | - | - | - |
| Total Shareholders Equity | 159.8M | 145.4M | 393.5M | 393.8M | 406.2M |
| Key Metrics | |||||
| Total Debt | 181.5M | 224.7M | 186.1M | 221.1M | 146.7M |
| Working Capital | -61.3M | 65.0M | 75.6M | 76.3M | 271.2M |
Balance Sheet Composition
Mesa Laboratories Cash Flow Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | -2.0M | -254.2M | 930.0K | 1.9M | 3.3M |
| Depreciation & Amortization | 24.5M | 31.6M | 33.1M | 25.1M | 17.7M |
| Stock-Based Compensation | 13.1M | 11.9M | 12.5M | 11.4M | 9.3M |
| Working Capital Changes | -3.1M | 7.0M | -13.2M | -3.8M | 2.7M |
| Operating Cash Flow | 39.7M | -229.4M | 31.9M | 42.6M | 34.5M |
| Investing Activities | |||||
| Capital Expenditures | -4.2M | -2.6M | -4.5M | -4.4M | -2.0M |
| Acquisitions | 0 | -78.7M | -5.0M | -300.8M | 0 |
| Investment Purchases | - | - | - | - | - |
| Investment Sales | - | - | - | - | - |
| Investing Cash Flow | -4.2M | -81.3M | -9.5M | -305.2M | -2.0M |
| Financing Activities | |||||
| Share Repurchases | - | - | - | - | - |
| Dividends Paid | -3.5M | -3.4M | -3.4M | -3.3M | -3.2M |
| Debt Issuance | 73.5M | 71.0M | 0 | 70.0M | 0 |
| Debt Repayment | -115.8M | -33.5M | -36.0M | -21.0M | 0 |
| Financing Cash Flow | -47.2M | 32.5M | -40.3M | 44.5M | 141.3M |
| Free Cash Flow | 42.3M | 41.6M | 23.4M | 34.8M | 35.1M |
| Net Change in Cash | -11.7M | -278.2M | -18.0M | -218.1M | 173.8M |
Cash Flow Trend
Mesa Laboratories Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
156.38
Forward P/E
18.86
Price to Book
3.01
Price to Sales
2.27
PEG Ratio
-0.50
Profitability Ratios
Profit Margin
1.51%
Operating Margin
12.25%
Return on Equity
2.18%
Return on Assets
2.47%
Financial Health
Current Ratio
1.94
Debt to Equity
91.07
Beta
0.89
Per Share Data
EPS (TTM)
$0.65
Book Value per Share
$33.79
Revenue per Share
$45.10
Peer Financial Comparison
| Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
|---|---|---|---|---|---|---|
| MLAB | 535.4M | 156.38 | 3.01 | 2.18% | 1.51% | 91.07 |
| Coherent | 63.0B | 334.34 | 7.41 | 3.24% | 4.66% | 39.90 |
| Keysight | 59.4B | 59.84 | 9.38 | 17.22% | 16.95% | 44.67 |
| Ituran Location and | 1.1B | 19.27 | 5.13 | 28.86% | 16.15% | 2.11 |
| Faro Technologies | 849.8M | - | 3.25 | -0.34% | -0.26% | 35.44 |
| Vishay Precision | 768.5M | 143.28 | 2.26 | 1.62% | 1.72% | 13.23 |
Financial data is updated regularly. All figures are in the company's reporting currency.






